CGT respiratory landscape remains challenging, but future still looks promising

One of the biggest challenges to the cell and gene therapy (CGT) landscape over the last couple of years has been the reduction in venture financing from $7.5 billion in 2021 to $3.3 billion in 2024. In the respiratory space, there has been very little development of CGT assets, with no approved therapy currently and only one product in an ongoing Phase III trial.

Despite these challenges, an evolving CGT pipeline landscape for respiratory diseases, coupled along with ongoing research and development efforts within the wider CGT space, holds promise for this treatment modality, says pharma analytics company GlobalData.

According to GlobalData’s pharmaceutical intelligence center, the Phase III asset is TasDes-02 by Iranian firm Taskin Bioregeneration, which is being developed to treat acute respiratory distress syndrome. One promising pipeline asset is 4D-710 by 4D Molecular Therapeutics (Nasdaq: FDMT) to treat patients with cystic fibrosis (CF).